Pfizer's Dividend Yield Attracts Income Investors Despite Challenges

Pfizer offers a 6.9% dividend yield, significantly higher than the S&P 500's 1% yield, despite challenges in COVID vaccine sales and drug development. The stock has fallen 60% from its 2021 peak. Pfizer's strong history and near-term uncertainty present a potential opportunity for long-term investors.

Pfizer PFE has become a focal point for income investors, offering a dividend yield near 7%, several times the S&P 500's roughly 1% . That elevated yield, however, is partly a function of a depressed share price rather than dividend growth alone.

The stock has fallen roughly 60% from its 2021 pandemic-era peak as COVID-19 vaccine and antiviral revenue faded and the company stumbled in the high-growth GLP-1 weight-loss category, abandoning its internally developed oral candidate . Pfizer has since moved to fill the gap through M&A, including a contested roughly $10 billion acquisition of Metsera that bought it a seat at the metabolic-disease table.

With an adjusted-earnings payout ratio near 60%, management retains room to defend the dividend through the transition. For PFE, the key variables are pipeline execution and whether new launches and acquisitions can offset patent-cliff and COVID-related revenue erosion; the high yield compensates for, rather than eliminates, the near-term uncertainty.